Information Provided By: 
Fly News Breaks for August 30, 2019
ORTX
Aug 30, 2019 | 07:51 EDT
Oppenheimer analyst Esther Rajavelu last night initiated coverage of Orchard Therapeutics with an Outperform rating and $26 price target. Orchard represents a "unique" investment opportunity, as it may evolve into a fully integrated biopharmaceutical company focused on lentiviral vector-based gene therapies to treat rare diseases, Rajavelu tells investors in a research note. With six assets in the clinic, the analyst believes the could be entering a phase of rapid developmental milestones over the next 12 to 18 months.
News For ORTX From the Last 2 Days
There are no results for your query ORTX
